Is neutralizing vitreal growth factors a viable strategy to prevent proliferative vitreoretinopathy?

Steven Pennock, Luis Haddock, Dean Eliott, Shizuo Mukai, Andrius Kazlauskas

Research output: Contribution to journalArticle

66 Citations (Scopus)

Abstract

Proliferative vitreoretinopathy (PVR) is a blinding disorder that occurs in eyes with rhegmatogenous retinal detachment and in eyes that have recently undergone retinal detachment surgery. There are presently no treatment strategies to reduce the risk of developing PVR in eyes with retinal detachment, and surgical intervention is the only option for eyes with retinal detachment and established PVR. Given the poor visual outcome associated with the surgical treatment of PVR, considerable work has been done to identify pharmacologic agents that could antagonize the PVR process. Intensive efforts to identify molecular determinants of PVR implicate vitreal growth factors. A surprise that emerged in the course of testing the 'growth factor hypothesis' of PVR was the existence of a functional relationship amongst growth factors that engage platelet-derived growth factor (PDGF) receptor α (PDGFRα), a receptor tyrosine kinase that is key to pathogenesis of experimental PVR. Vascular endothelial cell growth factor A (VEGF), which is best known for its ability to activate VEGF receptors (VEGFRs) and induce permeability and/or angiogenesis, enables activation of PDGFRα by a wide spectrum of vitreal growth factors outside of the PDGF family (non-PDGFs) in a way that triggers signaling events that potently enhance the viability of cells displaced into vitreous. Targeting these growth factors or signaling events effectively neutralizes the bioactivity of PVR vitreous and prevents PVR in a number of preclinical models. In this review, we discuss recent conceptual advances in understanding the role of growth factors in PVR, and consider the tangible treatment strategies for clinical application.

Original languageEnglish (US)
Pages (from-to)16-34
Number of pages19
JournalProgress in Retinal and Eye Research
Volume40
DOIs
StatePublished - 2014
Externally publishedYes

Fingerprint

Proliferative Vitreoretinopathy
Intercellular Signaling Peptides and Proteins
Retinal Detachment
Platelet-Derived Growth Factor Receptors
Vascular Endothelial Growth Factor Receptor
Platelet-Derived Growth Factor
Receptor Protein-Tyrosine Kinases
Vascular Endothelial Growth Factor A
Permeability
Cell Survival

Keywords

  • Growth factors
  • PDGFR
  • Proliferative vitreoretinopathy
  • Retinal detachment
  • Signaling
  • Vitreous

ASJC Scopus subject areas

  • Sensory Systems
  • Ophthalmology
  • Medicine(all)

Cite this

Is neutralizing vitreal growth factors a viable strategy to prevent proliferative vitreoretinopathy? / Pennock, Steven; Haddock, Luis; Eliott, Dean; Mukai, Shizuo; Kazlauskas, Andrius.

In: Progress in Retinal and Eye Research, Vol. 40, 2014, p. 16-34.

Research output: Contribution to journalArticle

Pennock, Steven ; Haddock, Luis ; Eliott, Dean ; Mukai, Shizuo ; Kazlauskas, Andrius. / Is neutralizing vitreal growth factors a viable strategy to prevent proliferative vitreoretinopathy?. In: Progress in Retinal and Eye Research. 2014 ; Vol. 40. pp. 16-34.
@article{3ec27080d8834cb3ba61bc15325ca9c1,
title = "Is neutralizing vitreal growth factors a viable strategy to prevent proliferative vitreoretinopathy?",
abstract = "Proliferative vitreoretinopathy (PVR) is a blinding disorder that occurs in eyes with rhegmatogenous retinal detachment and in eyes that have recently undergone retinal detachment surgery. There are presently no treatment strategies to reduce the risk of developing PVR in eyes with retinal detachment, and surgical intervention is the only option for eyes with retinal detachment and established PVR. Given the poor visual outcome associated with the surgical treatment of PVR, considerable work has been done to identify pharmacologic agents that could antagonize the PVR process. Intensive efforts to identify molecular determinants of PVR implicate vitreal growth factors. A surprise that emerged in the course of testing the 'growth factor hypothesis' of PVR was the existence of a functional relationship amongst growth factors that engage platelet-derived growth factor (PDGF) receptor α (PDGFRα), a receptor tyrosine kinase that is key to pathogenesis of experimental PVR. Vascular endothelial cell growth factor A (VEGF), which is best known for its ability to activate VEGF receptors (VEGFRs) and induce permeability and/or angiogenesis, enables activation of PDGFRα by a wide spectrum of vitreal growth factors outside of the PDGF family (non-PDGFs) in a way that triggers signaling events that potently enhance the viability of cells displaced into vitreous. Targeting these growth factors or signaling events effectively neutralizes the bioactivity of PVR vitreous and prevents PVR in a number of preclinical models. In this review, we discuss recent conceptual advances in understanding the role of growth factors in PVR, and consider the tangible treatment strategies for clinical application.",
keywords = "Growth factors, PDGFR, Proliferative vitreoretinopathy, Retinal detachment, Signaling, Vitreous",
author = "Steven Pennock and Luis Haddock and Dean Eliott and Shizuo Mukai and Andrius Kazlauskas",
year = "2014",
doi = "10.1016/j.preteyeres.2013.12.006",
language = "English (US)",
volume = "40",
pages = "16--34",
journal = "Progress in Retinal and Eye Research",
issn = "1350-9462",
publisher = "Elsevier Limited",

}

TY - JOUR

T1 - Is neutralizing vitreal growth factors a viable strategy to prevent proliferative vitreoretinopathy?

AU - Pennock, Steven

AU - Haddock, Luis

AU - Eliott, Dean

AU - Mukai, Shizuo

AU - Kazlauskas, Andrius

PY - 2014

Y1 - 2014

N2 - Proliferative vitreoretinopathy (PVR) is a blinding disorder that occurs in eyes with rhegmatogenous retinal detachment and in eyes that have recently undergone retinal detachment surgery. There are presently no treatment strategies to reduce the risk of developing PVR in eyes with retinal detachment, and surgical intervention is the only option for eyes with retinal detachment and established PVR. Given the poor visual outcome associated with the surgical treatment of PVR, considerable work has been done to identify pharmacologic agents that could antagonize the PVR process. Intensive efforts to identify molecular determinants of PVR implicate vitreal growth factors. A surprise that emerged in the course of testing the 'growth factor hypothesis' of PVR was the existence of a functional relationship amongst growth factors that engage platelet-derived growth factor (PDGF) receptor α (PDGFRα), a receptor tyrosine kinase that is key to pathogenesis of experimental PVR. Vascular endothelial cell growth factor A (VEGF), which is best known for its ability to activate VEGF receptors (VEGFRs) and induce permeability and/or angiogenesis, enables activation of PDGFRα by a wide spectrum of vitreal growth factors outside of the PDGF family (non-PDGFs) in a way that triggers signaling events that potently enhance the viability of cells displaced into vitreous. Targeting these growth factors or signaling events effectively neutralizes the bioactivity of PVR vitreous and prevents PVR in a number of preclinical models. In this review, we discuss recent conceptual advances in understanding the role of growth factors in PVR, and consider the tangible treatment strategies for clinical application.

AB - Proliferative vitreoretinopathy (PVR) is a blinding disorder that occurs in eyes with rhegmatogenous retinal detachment and in eyes that have recently undergone retinal detachment surgery. There are presently no treatment strategies to reduce the risk of developing PVR in eyes with retinal detachment, and surgical intervention is the only option for eyes with retinal detachment and established PVR. Given the poor visual outcome associated with the surgical treatment of PVR, considerable work has been done to identify pharmacologic agents that could antagonize the PVR process. Intensive efforts to identify molecular determinants of PVR implicate vitreal growth factors. A surprise that emerged in the course of testing the 'growth factor hypothesis' of PVR was the existence of a functional relationship amongst growth factors that engage platelet-derived growth factor (PDGF) receptor α (PDGFRα), a receptor tyrosine kinase that is key to pathogenesis of experimental PVR. Vascular endothelial cell growth factor A (VEGF), which is best known for its ability to activate VEGF receptors (VEGFRs) and induce permeability and/or angiogenesis, enables activation of PDGFRα by a wide spectrum of vitreal growth factors outside of the PDGF family (non-PDGFs) in a way that triggers signaling events that potently enhance the viability of cells displaced into vitreous. Targeting these growth factors or signaling events effectively neutralizes the bioactivity of PVR vitreous and prevents PVR in a number of preclinical models. In this review, we discuss recent conceptual advances in understanding the role of growth factors in PVR, and consider the tangible treatment strategies for clinical application.

KW - Growth factors

KW - PDGFR

KW - Proliferative vitreoretinopathy

KW - Retinal detachment

KW - Signaling

KW - Vitreous

UR - http://www.scopus.com/inward/record.url?scp=84899048922&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84899048922&partnerID=8YFLogxK

U2 - 10.1016/j.preteyeres.2013.12.006

DO - 10.1016/j.preteyeres.2013.12.006

M3 - Article

C2 - 24412519

AN - SCOPUS:84899048922

VL - 40

SP - 16

EP - 34

JO - Progress in Retinal and Eye Research

JF - Progress in Retinal and Eye Research

SN - 1350-9462

ER -